scholarly journals How Oral Specialists Can Help Diagnose and Manage Extra-Digestive Inflammatory Bowel Disease Complications

2021 ◽  
pp. 276-281
Author(s):  
Charlotte Thomas ◽  
Mylène Dimmock ◽  
Cyrielle Gilletta de Saint-Joseph ◽  
Béatrice Barres ◽  
Carle Paul ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Oral Cavity ◽  
Bowel Disease ◽  
Concept Map ◽  
Close Link ◽  
First Case ◽  
Intestinal Pathology ◽  
Gingival Enlargement ◽  
Inflammatory Bowel ◽  
Oral Complication

Identification of extra-digestive manifestations of inflammatory bowel disease (IBD) is essential. The oral cavity is a preferential site in which gingival enlargement may be one of these manifestations. We present, in this article, two original cases and a concept map that highlights the need for a close collaboration between the dental surgeon or oral specialist, the dermatologist, and the gastroenterologist. In the first case, the strictly local management of a systemic IBD oral complication, can relieve and answer the patient’s complaint without modifying or disrupting the systemic treatment already implemented by the gastroenterologists. In the second case, the dental surgeon’s diagnosis of gingival enlargement turns out to be the inaugural manifestation of Crohn’s disease and allows early treatment of the intestinal pathology. These two cases illustrate the close link between the oral cavity and IBD. Knowledge and multidisciplinary management of these manifestations such as proposed in the concept map are essential for clinicians for the early diagnosis and the improvement of the oral and general quality of life of patients suffering from IBD.

scholarly journals Expression of inflammatory mediators in biofilm samples and clinical association in inflammatory bowel disease patients—a preliminary study

2021 ◽  
Author(s):  
Mayte Buchbender ◽  
Jakob Fehlhofer ◽  
Peter Proff ◽  
Tobias Möst ◽  
Jutta Ries ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Inflammatory Bowel Disease ◽  
Oral Cavity ◽  
Bowel Disease ◽  
Trial Registry ◽  
Clinical Trial Registry ◽  
Clinical Trial Registration ◽  
Expression Levels ◽  
Inflammatory Bowel ◽  
Group 2

Abstract Objectives Inflammatory bowel disease (IBD) has multiple impacts on soft and hard tissues in the oral cavity. The aim of this study was to analyze the expression of cytokines in biofilm samples from patients suffering from IBD and compare them to healthy patients. It was hypothesized that different cytokine expression levels and clinical associations might be drawn. Material and methods A total of 56 biofilm samples from three different patient cohorts (group 0 = healthy, HC n = 30; group 1 = Crohn’s disease, CD, n = 19; group 2 = ulcerative colitis, UC, n = 7) were examined for the expression levels of the cytokine interleukins IL-2, -6, and -10; matrix metalloproteinases 7 and 9; and surface antigens CD90/CD11a by quantitative real-time PCR and according to clinical parameters (plaque index, BOP, PD, DMFT, CAL). Relative gene expression was determined using the ∆∆CT method. Results The mean BOP values (p = 0.001) and PD (p = 0.000) were significantly higher in the CD group compared to controls. Expression of IL-10 was significantly higher in the CD (p = 0.004) and UC groups (p = 0.022). Expression of MMP-7 was significantly higher in the CD group (p = 0.032). IBD patients treated with TNF inhibitors (p = 0.007) or other immunosuppressants (p = 0.014) showed significant overexpression of IL-10 compared to controls. Conclusion Different expression levels of IL-10 and MMP-7 were detected in plaque samples from IBD patients. As only BOP was significantly increased, we conclude that no clinical impairment of periodontal tissue occurred in IBD patients. Clinical relevance With the worldwide increasing incidence of IBD, it is important to obtain insights into the effects of the disease on the oral cavity. The study was registered (01.09.2020) at the German clinical trial registry (DRKS00022956). Clinical trial registration The study is registered at the German clinical trial registry (DRKS00022956).

scholarly journals Mosaic Tetrasomy 9p Associated With Inflammatory Bowel Disease

2019 ◽  
Vol 13 (11) ◽  
pp. 1474-1478 ◽  
Author(s):  
Luis Sifuentes-Dominguez ◽  
Petro Starokadomskyy ◽  
Jacob Welch ◽  
Bhaskar Gurram ◽  
Jason Y Park ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Intestinal Inflammation ◽  
Type I Interferon ◽  
Organ Damage ◽  
Genomic Region ◽  
Chromosome 9 ◽  
Type I ◽  
First Case ◽  
Inflammatory Bowel

Abstract The genetic basis of inflammatory bowel disease remains to be elucidated completely. Here we report on a patient with inflammatory bowel disease who has mosaic tetrasomy of the short arm of chromosome 9, a genomic region that harbours the type I interferon gene cluster. We show that increased interferon activation is present in peripheral blood and intestinal tissue from this patient, similar to previous reports of autoinflammatory organ damage driven by interferon activation in other patients with this chromosomal abnormality. To our knowledge, this is the first case of tetrasomy 9p-associated interferonopathy driving intestinal inflammation and highlights the role that type-I interferon pathways can play in the pathogenesis of intestinal inflammation.

scholarly journals Genetic Dissection of the Cellular Pathways and Signaling Mechanisms in Modeled Tumor Necrosis Factor–induced Crohn's-like Inflammatory Bowel Disease

2002 ◽  
Vol 196 (12) ◽  
pp. 1563-1574 ◽  
Author(s):  
Dimitris Kontoyiannis ◽  
George Boulougouris ◽  
Menelaos Manoloukos ◽  
Maria Armaka ◽  
Maria Apostolaki ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bone Marrow ◽  
Tumor Necrosis Factor ◽  
Bowel Disease ◽  
Tumor Necrosis ◽  
Interleukin 12 ◽  
Intestinal Pathology ◽  
Inflammatory Bowel ◽  
Cellular Pathways ◽  
Necrosis Factor

Recent clinical evidence demonstrated the importance of tumor necrosis factor (TNF) in the development of Crohn's disease. A mouse model for this pathology has previously been established by engineering defects in the translational control of TNF mRNA (TnfΔAREmouse). Here, we show that development of intestinal pathology in this model depends on Th1-like cytokines such as interleukin 12 and interferon γ and requires the function of CD8+ T lymphocytes. Tissue-specific activation of the mutant TNF allele by Cre/loxP-mediated recombination indicated that either myeloid- or T cell–derived TNF can exhibit full pathogenic capacity. Moreover, reciprocal bone marrow transplantation experiments using TNF receptor–deficient mice revealed that TNF signals are equally pathogenic when directed independently to either bone marrow–derived or tissue stroma cell targets. Interestingly, TNF-mediated intestinal pathology was exacerbated in the absence of MAPKAP kinase 2, yet strongly attenuated in a Cot/Tpl2 or JNK2 kinase–deficient genetic background. Our data establish the existence of redundant cellular pathways operating downstream of TNF in inflammatory bowel disease, and demonstrate the therapeutic potential of selective kinase blockade in TNF-mediated intestinal pathology.

scholarly journals Pathogenetic Aspects of Oral Cavity Lesions in Inflammatory Gastrointestinal Tract Diseases

2019 ◽  
Vol 29 (4) ◽  
pp. 15-21
Author(s):  
N. S. Robakidze ◽  
O. B. Shchukina
Keyword(s):  
Inflammatory Bowel Disease ◽  
Gastrointestinal Tract ◽  
Oral Cavity ◽  
Bowel Disease ◽  
Pathological Process ◽  
Digestive Tube ◽  
Close Relationship ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Immunohistochemical Studies

Despite the similarity of many pathogenetic lesions of the gastrointestinal tract and the oral cavity, there remain unresolved issues related to the etiology and pathogenesis of dental diseases associated with inflammatory bowel diseases.Aim. Analysis and systematization of literature data on the problem of combined diseases of the oral cavity and the gastrointestinal tract.Key findings. Severe recurrent inflammatory bowel disease and the close relationship of all levels of the digestive tube create prerequisites for the development of pathological processes in the oral cavity. Despite the extensive symptoms of oral manifestations of inflammatory bowel disease, aphthous stomatitis is considered more often than other diseases. There are different opinions about the involvement of the oral mucosa in the pathological process in inflammatory bowel disease. Some authors consider the defeat of the mouth in terms of the specific localization of Crohn’s disease, others see in it only extraintestinal manifestations of the disease, along with changes in the skin, joints and eyes. Immunohistochemical studies allow you to answer individual questions of pathogenesis.Conclusion. The presented analysis of publications confirms the morphofunctional unity of various parts of the digestive system, which determines the complex mechanisms of the development of combined diseases.

scholarly journals Pericardial Manifestations in Inflammatory Bowel Disease: A Report of Two Cases

2019 ◽  
Vol 1 (3) ◽  
Author(s):  
T Qazi ◽  
K E Christian ◽  
F A Farraye ◽  
R K Cross
Keyword(s):  
Inflammatory Bowel Disease ◽  
Adverse Event ◽  
Crohn Disease ◽  
Bowel Disease ◽  
Case Series ◽  
Acute Pericarditis ◽  
Pericardial Disease ◽  
Clinical Recurrence ◽  
First Case ◽  
Inflammatory Bowel

Abstract Pericardial involvement in the setting of inflammatory bowel disease can occur not only as an adverse event related to medical therapy but also as an extraintestinal manifestation of the disease itself. In the following case series, we describe 2 cases of pericarditis in patients diagnosed with Crohn disease. Our first case reviews the clinical presentation of acute pericarditis as an adverse event associated with anti-tumor necrosis factor therapy. In contrast, our second patient is a case of acute pericarditis as a precursor of the clinical recurrence of Crohn disease following operative resection. Pericardial disease should be considered in the differential diagnosis of acute and subacute presentations of chest discomfort and shortness of breath in patients with inflammatory bowel disease.

scholarly journals Salivary and Serum Inflammatory Profiles Reflect Different Aspects of Inflammatory Bowel Disease Activity

2020 ◽  
Vol 26 (10) ◽  
pp. 1588-1596 ◽  
Author(s):  
Mirjam Majster ◽  
Ronaldo Lira-Junior ◽  
Charlotte M Höög ◽  
Sven Almer ◽  
Elisabeth A Boström
Keyword(s):  
Inflammatory Bowel Disease ◽  
Oral Cavity ◽  
Disease Activity ◽  
Bowel Disease ◽  
Intestinal Inflammation ◽  
Serum Proteins ◽  
Biochemical Status ◽  
Whole Saliva ◽  
Inflammatory Bowel ◽  
Inflammatory Proteins

Abstract Background Inflammatory bowel disease (IBD) can manifest both macroscopically and microscopically in the oral cavity; however, little is known about salivary changes in IBD. Therefore, this study aimed to assess salivary and circulatory inflammatory profiles in IBD and to compare their potential to reflect the presence and activity of IBD. Methods We measured 92 known inflammatory proteins in serum and in unstimulated and stimulated whole saliva samples from patients with IBD with active intestinal inflammation (n = 21) and matched control patients (n = 22) by proximity extension assay. Fifteen of the patients with IBD returned 10 to 12 weeks after treatment escalation for resampling. Results Sixty-seven of the proteins were detected in all 3 sample fluids but formed distinct clusters in serum and saliva. Twenty-one inflammatory proteins were significantly increased and 4 were significantly decreased in the serum of patients with IBD compared with that of the control patients. Two of the increased serum proteins, IL-6 and MMP-10, were also significantly increased in stimulated saliva of patients with IBD and correlated positively to their expressions in serum. None of the investigated proteins in serum or saliva were significantly altered by IBD treatment at follow-up. Overall, inflammatory proteins in serum correlated to biochemical status, and salivary proteins correlated positively to clinical parameters reflecting disease activity. Conclusions Saliva and serum inflammatory profiles in IBD share a similar composition but reflect different aspects of disease activity. The oral cavity reflects IBD through elevated IL-6 and MMP-10 in stimulated saliva.

Acquired Fanconi syndrome in four cats treated with chlorambucil

2016 ◽  
Vol 18 (12) ◽  
pp. 1034-1040 ◽  
Author(s):  
Natalie C Reinert ◽  
David G Feldman
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Complete Resolution ◽  
Fanconi Syndrome ◽  
Clinical Signs ◽  
Case Series ◽  
Biochemical Screening ◽  
Disease Treatment ◽  
First Case ◽  
Inflammatory Bowel

Case series summary Fanconi syndrome (FS) is well described in humans and dogs, but has not been reported in cats. This case series describes four cats with acquired FS. On the basis of clinical signs and intestinal biopsies, all cats were initially diagnosed with alimentary lymphoma or inflammatory bowel disease. Treatment with chlorambucil and corticosteroids was started at standard doses, based on published protocols. Within 2–26 months of the start of treatment, glucosuria, despite normoglycemia, was identified incidentally on routine biochemical screening; FS was diagnosed with urine metabolic assays, confirming aminoaciduria and glucosuria in all four cases. Neither polyuria nor polydipsia were noted in any case, and only 1/4 cats had any clinical signs at the time of diagnosis. Partial or complete resolution of FS was seen in 3/4 cases within 3 months of discontinuing chlorambucil therapy. Relevance and novel information This is the first case series to document acquired FS in the cat, and the first to suggest a possible association between chlorambucil and acquired FS. Cats treated with chlorambucil should be monitored for the development of glucosuria, and discontinuation of chlorambucil should be considered if FS is identified. Further study into the association between chlorambucil and acquired FS in cats is warranted.

scholarly journals Elevated IgA and IL-10 levels in very-early-onset inflammatory bowel disease secondary to IL-10 receptor deficiency

2022 ◽  
Vol 40 ◽  
Author(s):  
Natascha Silva Sandy ◽  
Lia Furlaneto Marega ◽  
Giane Dantas Bechara ◽  
Adriana Gut Lopes Riccetto ◽  
Carmen Bonfim ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Early Onset ◽  
Hematopoietic Cell Transplantation ◽  
Case Reports ◽  
Cytokine Profile ◽  
Plasma Cytokine ◽  
First Case ◽  
Tertiary Center ◽  
Inflammatory Bowel

ABSTRACT Objective: To report two patients with very-early-onset inflammatory bowel disease (VEOIBD) secondary to interleukin-10 receptor (IL-10R) mutations, explore immunophenotyping data and plasma cytokine profile on these cases compared to healthy controls, and describe the phenotype of IL-10/IL-10R mutations based on a literature review. Case description: We report on two female infants referred to our tertiary center at the age of ten months, with severe colonic and perianal disease, as well as significant malnutrition, who had shown limited response to usual inflammatory bowel disease (IBD) therapy agents. In the first case, whole-exome sequencing (WES) revealed a homozygous (c.537G>A/p.T179T) mutation in exon 4 of the IL-10RA gene, while in the second patient, compound heterozygosity was identified, also in the IL-10RA gene (chr11:117.859.199 variant A>G/p.Tyr57Cys and chr11: 117.860.335 variant G>T/p.Val123Leu). Both patients underwent hematopoietic cell transplantation (HCT). Immunological work-up of these patients revealed increased IL-10 plasma levels and increased IgA. Comments: Our case reports disclose novel findings on plasma cytokine profile in IL-10R deficiency, and we describe the severe phenotype of IL-10/IL-10R deficiency that should be recognized by physicians.

Sign in / Sign up

Export Citation Format

Share Document